AbbVie

Official global handle sharing the latest news about our company, science & people. Review our guidelines:

[AbbVie @abbvie]

[Video description: On-screen text reads, "Immunology News"]

[AbbVie @abbvie]

We've signed a definitive agreement to acquire Apogee Therapeutics. The proposed acquisition will deepen our #immunology portfolio with differentiated assets focused on dermatologic, respiratory and other related inflammatory diseases. Learn more: https://t.co/RyjhLw8imP

[AbbVie @abbvie]

@AshDHarrington Hi @AshDHarrington , we saw your post and would like to connect. Can you DM us with more information?

[AbbVie @abbvie]

[Video description: Johannes Förner, CLL Patient, discusses the impact of shared decision making]

[AbbVie @abbvie]

Shared decision-making empowers people living with chronic lymphocytic leukemia (#CLL) like Johannes, to make informed choices that make them feel confident in their care. Hear from Johannes about his experience.
#LifeInFreedom #EHA2026

[AbbVie @abbvie]

We’re presenting data at @EHA_Hematology across chronic lymphocytic leukemia (#CLL), including combination treatment efficacy and safety profiles.
Learn more: https://t.co/WVcGaGZpu4

[AbbVie @abbvie]

[“...can be a challenge for patients facing DLBCL and FL, as many experience relapse.”]

[AbbVie @abbvie]

During #EHA2026, we’re sharing more about the latest advancements in blood cancer research, including diffuse large B-cell lymphoma and follicular lymphoma. We are focused on our commitment to helping improve outcomes for people living with #BloodCancer.

[AbbVie @abbvie]

[Video description: On-screen text reads, “Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are two common subtypes of non-Hodgkin lymphoma (NHL). DLBCL accounts for 25-30% of all NHL cases, and FL accounts for 20-30% of all NHL cases. Treatment management...”]

[AbbVie @abbvie]

At @EHA_Hematology, we’ll be showcasing our clinical advancements across multiple blood cancers and connecting with the global community. https://t.co/u1xNRYNPrO

[AbbVie @abbvie]

At #EULAR2026, conversations on the ground are focused on how to achieve and maintain disease control in #PsA and #axSpA. AbbVie is on-site, sharing new research and a commitment to improving patient outcomes. Learn more: https://t.co/H2rNBLvGuV

[AbbVie @abbvie]

[Animation description: Diverse profile illustrations transition to on-screen text highlighting AbbVie's 26 accepted abstracts across five rheumatic diseases at EULAR 2026, closing with a 'See you there!' message.]

[AbbVie @abbvie]

At #EULAR2026, we're presenting abstracts across our #rheumatology portfolio. We remain committed to building on our deep expertise and historic legacy in immunology research. Explore what drives us in immunology: https://t.co/H2rNBLvGuV

[AbbVie @abbvie]

#DYK migraine is a prevalent and debilitating neurological disease, impacting roughly 14% of the global population, with a higher incidence in women than men?

Learn more about a new indication for the acute treatment of migraine: https://t.co/FSnJbbMRL2

[AbbVie @abbvie]

At #ASCO26, we're inviting #HCPs to stop by our booth and share their unique connection to the #oncology community – showing how each connection strengthens our commitment to science for this community. Join us at Booth 27093.

[AbbVie @abbvie]

@plantinBetty @HHSGov Hi @plantinBetty, we saw your post and would like to connect. Can you DM us with more information?

[AbbVie @abbvie]

[Video description: On-screen text reads, “Oncology News.”]

[AbbVie @abbvie]

The @EU_Commission has granted AbbVie approval of our medicine as part of a combination regimen for previously untreated patients with chronic lymphocytic leukemia (#CLL). https://t.co/hXy1xSvBh1

[AbbVie @abbvie]

[Video description: On-screen text reads, "AbbVie data at ASCO 2026. AbbVie will share new data across: Small cell lung cancer, Ovarian cancer, Head and neck cancer, Prostate cancer, Multiple myeloma."]

[AbbVie @abbvie]

At this year's @ASCO Annual Meeting, our team will share new data across solid tumors and blood cancers from our novel platforms. Read more: https://t.co/45tL2BDVSS #ASCO26